Margaret Gamble was supposed to receive a blood test in the mail in May. It’s a regularly scheduled test to check if her kidney — the second she’s received in a transplant — has been damaged in any way.
Her kidney needs to be constantly monitored since it’s vulnerable to infections or, critically, rejection by her immune system.
But Gamble’s test never came. Her doctor told her there’s been a billing issue with her Medicare insurance, and so now she’s waiting, not knowing how her kidney is doing and if she could be in danger of losing it.
Gamble, a 70-year-old resident of West Columbia, S.C., can’t undergo a biopsy of her kidney, which is the traditional way of monitoring transplants, since she’s on blood thinners and is at heightened risk of bleeding. And because she’s already had two kidney transplants, her body has developed antibodies that would make it difficult for her to get a third donated kidney.
That means if she loses this kidney, she’d likely have to go on dialysis for the rest of her life.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect